The firm maintains a structural 100% gross margin advantage, though revenue growth remains inconsistent, fluctuating between a 17% contraction in 2024Q1 and an 11% expansion by 2026Q1.
| Sales/Revenue | 2.44B | 2.38B | 2.26B | 2.35B | 2.24B | 2.29B | 2.12B | 1.81B | 1.79B | 1.6B |
| Revenue Growth % | 7.82% | 5.06% | -3.86% | 5.24% | -2.28% | 7.87% | 16.98% | 1.08% | 12.33% | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 1.81B | 2.38B | 2.26B | 2.35B | 2.24B | 2.29B | 2.12B | 1.81B | 1.79B | 1.6B |
| Gross Margin % | 74.15% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% |
| Gross Profit Growth % | - | 5.06% | -3.86% | 5.24% | -2.28% | 7.87% | 16.98% | 1.08% | 12.33% | - |
| Operating Expenses | 983.61M | 818.67M | 971.13M | 862.4M | 1.93B | 858.75M | 526.95M | -808.92M | 430.45M | 658.24M |
| OpEx % of Revenue | - | 34.42% | 42.9% | 36.63% | 86.27% | 37.51% | 24.83% | -44.59% | 23.98% | 41.19% |
| Selling, General & Admin | 621.77M | 573.48M | 236.67M | 249.75M | 227.3M | 182.83M | 181.72M | 103.44M | 61.91M | 106.44M |
| SG&A % of Revenue | - | 24.11% | 10.46% | 10.61% | 10.16% | 7.99% | 8.56% | 5.7% | 3.45% | 6.66% |
| Research & Development | 442M | 452M | 2M | 52M | 177.11M | 200.08M | 26.29M | 83.04M | 392.61M | 117.87M |
| R&D % of Revenue | - | 19.01% | 0.09% | 2.21% | 7.92% | 8.74% | 1.24% | 4.58% | 21.87% | 7.38% |
| Other Operating Expenses | 1000K | -206.81M | 732.46M | 560.66M | 1.53B | 475.84M | 318.95M | -995.4M | -24.07M | 433.93M |
| Operating Income | 1.59B | 1.56B | 1.29B | 1.49B | 307.06M | 1.43B | 1.6B | 2.62B | 1.36B | 939.69M |
| Operating Margin % | 65.07% | 65.58% | 57.1% | 63.37% | 13.73% | 62.49% | 75.17% | 144.59% | 76.02% | 58.81% |
| Operating Income Growth % | - | 20.66% | -13.38% | 385.94% | -78.54% | -10.32% | -39.18% | 92.25% | 45.2% | - |
| EBITDA | 1.54B | 1.56B | 1.56B | 1.89B | 312.74M | 1.45B | 1.62B | 2.65B | 1.4B | 972.96M |
| EBITDA Margin % | 63.1% | 65.74% | 68.76% | 80.15% | 13.98% | 63.5% | 76.26% | 145.91% | 77.87% | 60.89% |
| EBITDA Growth % | -23.56% | 0.45% | -17.54% | 503.47% | -78.49% | -10.18% | -38.86% | 89.39% | 43.66% | - |
| D&A (Non-Cash Add-back) | 2.47M | 3.85M | 0 | 0 | 5.67M | 23M | 23.06M | 23.92M | 33.27M | 33.27M |
| EBIT | 1.13B | 1.63B | 1.56B | 1.89B | 418.02M | 1.41B | 1.86B | 2.73B | 1.8B | 1.59B |
| Net Interest Income | -314.1M | -274.07M | -178.17M | -114.9M | -109.63M | -112.61M | -128.68M | -246.24M | -255.51M | -240.58M |
| Interest Income | 22.3M | 33.59M | 47.34M | 72.29M | 78.33M | 53.53M | 28.38M | 22.33M | 24.44M | 6.76M |
| Interest Expense | 336.4M | 307.66M | 225.51M | 187.19M | 187.96M | 166.14M | 157.06M | 268.57M | 279.96M | 247.34M |
| Other Income/Expense | -229.58M | -235.33M | 38.37M | 207.94M | -77M | -189.51M | 106.56M | -161.76M | 153.41M | 403.49M |
| Pretax Income | 1.36B | 1.32B | 1.33B | 1.7B | 230.06M | 1.24B | 1.7B | 2.46B | 1.52B | 1.34B |
| Pretax Margin % | 55.67% | 55.68% | 58.79% | 72.2% | 10.28% | 54.21% | 80.19% | 135.67% | 84.57% | 84.06% |
| Income Tax | 173M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 12.73% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | 827.6M | 770.95M | 858.98M | 1.13B | 42.83M | 619.73M | 975.04M | 2.35B | 1.38B | 1.21B |
| Net Margin % | 33.9% | 32.42% | 37.95% | 48.2% | 1.91% | 27.07% | 45.94% | 129.45% | 76.76% | 75.72% |
| Net Income Growth % | -24.25% | -10.25% | -24.31% | 2549.5% | -93.09% | -36.44% | -58.48% | 70.46% | 13.86% | - |
| Net Income (Continuing) | 1.19B | 1.32B | 1.33B | 1.7B | 230.06M | 1.24B | 1.7B | 2.46B | 1.52B | 1.34B |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 3.05B | 3.24B | 3.4B | 3.56B | 3.9B | 4.47B | 5.08B | 35.88M | 63.87M | 0 |
| EPS (Diluted) | 1.48 | 1.80 | 1.91 | 2.53 | 0.10 | 1.49 | 1.28 | 6.63 | 3.89 | 3.42 |
| EPS Growth % | -23.71% | -5.76% | -24.51% | 2430% | -93.29% | 16.41% | -80.69% | 70.44% | 13.74% | - |
| EPS (Basic) | - | 2.33 | 1.92 | 3.41 | 0.10 | 1.49 | 1.28 | 6.63 | 3.89 | 3.42 |
| Diluted Shares Outstanding | 559.61M | 559.61M | 594M | 602.9M | 564.93M | 414.8M | 388.13M | 354.18M | 354.18M | 354.18M |
| Basic Shares Outstanding | 431.89M | 431.89M | 445.99M | 447.6M | 437.96M | 414.79M | 388.13M | 354.18M | 354.18M | 354.18M |
| Dividend Payout Ratio | - | 49.06% | 43.83% | 31.58% | 778.21% | 46.02% | 40.8% | 31.48% | 59.11% | 60.76% |
Patent cliff reinvestment risk
According to the provided quarterly data, RPRX's revenue growth has remained inconsistent, fluctuating between a 17% contraction in 2024Q1 and an 11% expansion by 2026Q1, suggesting that the firm's reliance on milestone payments creates significant lumpiness that obscures the underlying commercial performance of its royalty portfolio.
The volatility in top-line growth appears to be driven by the timing of milestone receipts rather than a steady expansion of the core royalty base. Investors should monitor whether the recent shift toward synthetic royalties can provide a more predictable growth trajectory compared to the historical reliance on traditional biotech asset acquisitions.
As reported in financial statements, RPRX consistently maintains a 100% gross margin, a structural characteristic of its royalty-based business model that allows the firm to bypass the manufacturing and distribution costs typically associated with the broader biotechnology industry, thereby insulating it from inflationary pressures on physical goods.
While gross margins are structurally perfect, operating margins have shown significant variance, ranging from negative territory in 2024Q1 to 94% in 2025Q1. This suggests that the firm's profitability is highly sensitive to the timing of R&D-related expenses and professional fees incurred during the due diligence process for new asset acquisitions.
Based on the income statement data, RPRX's cost structure is characterized by erratic R&D and SG&A spending, with R&D expenses spiking to $300.5 million in 2025Q2, which indicates that the company's expense discipline is heavily influenced by the specific nature and timing of its strategic investment activities.
The lack of a linear relationship between revenue and operating expenses suggests that management's cost structure is not purely administrative but is instead tied to the episodic nature of deal-making. This makes it difficult to forecast future operating income, as significant outlays for technical evaluations can compress margins in any given quarter.
As evidenced by the recent financial data, the company's net income is subject to significant volatility, with stock-based compensation reaching $125.8 million in 2025Q4, a factor that warrants further investigation to determine how much of the reported EPS is driven by operational success versus non-cash accounting adjustments.
The wide swings in quarterly EPS, such as the drop from $1.21 in 2024Q3 to $0.07 in 2025Q2, suggest that GAAP net income may be a poor proxy for the company's actual cash-generating capacity. Analysts should prioritize adjusted cash receipts to better understand the underlying economic value being created by the portfolio.
The market's focus on current royalty yields may overlook the substantial reinvestment risk identified in recent filings, as the company must continuously deploy massive amounts of capital to replace the cash flows from aging blockbuster assets that are approaching their respective patent cliffs and potential biosimilar competition.
If the internal rate of return on new acquisitions continues to face pressure from increased competition for life science assets, the company may struggle to maintain its historical growth rates. This potential for margin compression suggests that the current valuation may not fully account for the difficulty of sustaining a high-margin portfolio over the long term.
Quick answers to the most common questions about buying RPRX stock.
For fiscal year 2025, Royalty Pharma plc (RPRX) reported total revenue of $2.38B. This represents a 48.8% increase compared to $1.60B in 2017.
Royalty Pharma plc (RPRX) is profitable, generating $770.9M in net income for the fiscal year ending 2025 with a net profit margin of 32.4%.
Royalty Pharma plc (RPRX) reported an operating income of $1.56B, resulting in an operating profit margin of 65.6%. This margin reflects the operational efficiency of the business before interest and taxes.
Royalty Pharma plc (RPRX) generated $2.38B in gross profit for the year, representing a gross profit margin of 100.0%. This demonstrates the company's core pricing power and production efficiency.